Aclaris Therapeutics Inc’s filing revealed that its 10% Owner Leonard Braden Michael acquired Company’s shares for reported $0.26 million on Aug 05 ’24. In the deal valued at $1.24 per share,206,025 shares were bought. As a result of this transaction, Leonard Braden Michael now holds 14,250,000 shares worth roughly $24.08 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Leonard Braden Michael bought 167,544 shares, generating $216,400 in total proceeds. Upon buying the shares at $1.29, the 10% Owner now owns 14,043,975 shares.
Before that, Leonard Braden Michael bought 173,730 shares. Aclaris Therapeutics Inc shares valued at $226,370 were divested by the 10% Owner at a price of $1.30 per share. As a result of the transaction, Leonard Braden Michael now holds 13,776,421 shares, worth roughly $23.28 million.
H.C. Wainwright downgraded its Aclaris Therapeutics Inc [ACRS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including William Blair’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “a Mkt perform”. Evercore ISI began covering ACRS with “an Outperform” recommendation on October 03, 2023. Stifel started covering the stock on December 14, 2022. It rated ACRS as “a Buy”.
Price Performance Review of ACRS
On Friday, Aclaris Therapeutics Inc [NASDAQ:ACRS] saw its stock jump 31.01% to $1.69. Over the last five days, the stock has gained 42.02%. Aclaris Therapeutics Inc shares have risen nearly 60.95% since the year began. Nevertheless, the stocks have fallen -63.73% over the past one year. While a 52-week high of $5.70 was reached on 10/25/24, a 52-week low of $0.59 was recorded on 01/12/24. SMA at 50 days reached $1.1982, while 200 days put it at $1.2031.
Levels Of Support And Resistance For ACRS Stock
The 24-hour chart illustrates a support level at 1.4000, which if violated will result in even more drops to 1.1100. On the upside, there is a resistance level at 1.8450. A further resistance level may holdings at 2.0000. The Relative Strength Index (RSI) on the 14-day chart is 85.95, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1783, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 3.45%. Stochastics %K at 91.23% indicates the stock is a selling.
How much short interest is there in Aclaris Therapeutics Inc?
A steep rise in short interest was recorded in Aclaris Therapeutics Inc stocks on 2024-10-15, dropping by -0.32 million shares to a total of 1.39 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 1.71 million shares. There was a decline of -22.99%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 01, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
